Enzo Biochem Concludes Transition to Private Ownership

The biotechnology firm Enzo Biochem has completed its departure from public markets. The company’s shares have been delisted following its acquisition, concluding its lengthy tenure as a publicly traded entity. Shareholders have received their cash settlements, formally ending this chapter for investors.

The path to privatization was finalized through a merger with Bethpage Parent on August 20 of last year. This transaction represented the culmination of a broader strategic shift. Prior to the merger, Enzo Biochem had voluntarily terminated its listing on the New York Stock Exchange (NYSE) in April 2025, subsequently trading on the OTCQX market for an interim period.

As part of the merger agreement, all outstanding Read more...